scholarly journals Age increased the cancer‐specific mortality risk of thyroid cancer with lung metastasis

2022 ◽  
Author(s):  
Xiu Huang ◽  
Qing Xia ◽  
Yueye Huang ◽  
Aimei Peng ◽  
Jie Yang
Keyword(s):  
Thyroid Cancer ◽  
Lung Metastasis ◽  
Mortality Risk ◽  
Specific Mortality ◽  
Cancer Specific Mortality

scholarly journals Age Increased Cancer-specific Mortality Risk of Thyroid Cancer With Lung Metastasis

2021 ◽  
Author(s):  
Xiu Huang ◽  
Qing Xia ◽  
Shen Qu ◽  
Aimei Peng ◽  
Jie Yang
Keyword(s):  
Thyroid Cancer ◽  
Lung Metastasis ◽  
Distant Metastases ◽  
Individual Treatment ◽  
Kaplan Meier ◽  
Hazard Ratios ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
The Relationship

Abstract Background: To investigate the relationship between age and cancer-specific mortality in thyroid cancer (TC) with lung-metastasis.Methods: 1,418 patients with initial distant metastases from Surveillance, Epidemiology and End Results databases were investigated. Patients with median follow-up time of 8 months [interquartile range (IQR), 2–27] and median age of 66 years (IQR, 55-76) were divided into five groups by age and the association between age and TC-specific mortality was analyzed.Results: The TC-specific mortality rates were 32.78% (118/360), 46.71% (156/334), 53.93% (199/369), 58.96% (158/268) and 82.76% (72/87) for patients with age of ≤55 years,56-65 years, 66-75 years, 76-85 years and >85 years. Kaplan-Meier curves showed that TC-specific mortality rate was associated with increased age (p < 0.001). Compared with patients ≤55 years, patients of 56-65 years, 66-75 years, 76-85 years and >85 years had significantly higher hazard ratios (HRs) of 1.69(1.26-2.26), 1.97 (1.47-2.64), 2.18(1.59-2.99) and 3.24(2.08-5.06) after adjustments for gender, tumor size and radiation therapy (all p < 0.001).In TC with initial lung-metastasis, compared with patients ≤55 years, patients of 56-65 years, 66-75 years, 76-85 years and >85 years had significantly higher adjusted HRs of 1.68(1.20-2.36, p=0.003), 2.18(1.57-3.02), 2.16(1.51-3.08) and 2.91(1.79-4.75) (p < 0.001). Similar results could be obtained in papillary thyroid cancer.Conclusions: The TC-specific mortality increased with age in TC patients with initial lung-metastasis, which suggested that further risk stratification based on age was necessary for TC over 55 years with lung-metastasis. Individual treatment strategy maybe recommended for patients over 85 years.

scholarly journals TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 648
Author(s):  
Jun Park ◽  
Sungjoo Lee ◽  
Kyunga Kim ◽  
Hyunju Park ◽  
Chang-Seok Ki ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factor ◽  
Histologic Type ◽  
Stage At Diagnosis ◽  
Tert Promoter ◽  
Tert Promoter Mutations ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Promoter Mutations ◽  
8Th Edition

Our research group has previously shown that the presence of TERT promoter mutations is an independent prognostic factor, by applying the TERT mutation status to the variables of the AJCC 7th edition. This study aimed to determine if TERT mutations could be independent predictors of thyroid cancer-specific mortality based on the AJCC TNM 8th edition, with long-term follow-up. This was a retrospective study of 393 patients with pathologically confirmed differentiated thyroid carcinoma (DTC) after thyroidectomy at a tertiary Korean hospital from 1994 to 2004. The thyroid cancer-specific mortality rate was 6.9% (5.2% for papillary and 15.2% for follicular cancers). TERT promoter mutations were identified in 10.9% (43/393) of DTC cases (9.8% of papillary and 16.7% of follicular cancer) and were associated with older age (p < 0.001), the presence of extrathyroidal invasion (p < 0.001), distant metastasis (p = 0.001), and advanced stage at diagnosis (p < 0.001). The 10-year survival rate in mutant TERT was 67.4% for DTC patients (vs. 98% for wild-type; adjusted hazard ratio (HR) of 9.93, (95% CI: 3.67–26.90)) and 75% for patients with papillary cancer (vs. 99%; 18.55 (4.83–71.18)). In addition, TERT promoter mutations were related to poor prognosis regardless of histologic type (p < 0.001 for both papillary and follicular cancer) or initial stage (p < 0.001, p = 0.004, and p = 0.086 for stages I, II, and III and IV, respectively). TERT promoter mutations comprise an independent poor prognostic factor after adjusting for the clinicopathological risk factors of the AJCC TNM 8th edition, histologic type, and each stage at diagnosis, which could increase prognostic predictability for patients with DTC.

scholarly journals Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer

2014 ◽  
Vol 22 (8) ◽  
pp. 2700-2706 ◽  
Author(s):  
Allen S. Ho ◽  
Lu Wang ◽  
Frank L. Palmer ◽  
Changhong Yu ◽  
Arnbjorn Toset ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Specific Mortality ◽  
Cancer Specific Mortality

scholarly journals The Increased Risk of Thyroid Cancer-Specific Mortality With Tumor Size in Stage IVB Patients

2020 ◽  
Vol 10 ◽  
Author(s):  
Junyi Zhang ◽  
Xiaoyun Cheng ◽  
Bin Su ◽  
Xingchun Wang ◽  
Lu Wang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Size ◽  
Increased Risk ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Stage Ivb

scholarly journals Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Case–Control Cohort Study

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3955
Author(s):  
Yu-Ling Lu ◽  
Shu-Fu Lin ◽  
Ming-Hsien Wu ◽  
Yi-Yin Lee ◽  
Pai-Wei Lee ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Thyroid Cancer ◽  
Cancer Patients ◽  
Mortality Risk ◽  
Gender History ◽  
Specific Mortality ◽  
History Of ◽  
Related Mortality ◽  
Overall Mortality ◽  
Cvd Mortality

The incidence of thyroid cancer has increased substantially worldwide. However, the overall mortality risk and actual causes of death in thyroid cancer patients have not been extensively evaluated. In this study, patients with thyroid cancer diagnosed between 2001 and 2017 were analyzed from Taiwan’s National Health Insurance Research Database. We compared these patients with control subjects matched for age, gender, history of cardiovascular disease (CVD), hyperlipidemia, diabetes mellitus, hypertension, and occupation to assess the risk of overall mortality and cause-specific mortality. Finally, our cohort comprised 30,778 patients with thyroid cancer. Three hundred and ninety-eight deaths (1.29%) occurred during a median follow-up of 60.0 months (range: 30.3 to 117.6 months). The primary cause of death was thyroid cancer mortality (31.2%), followed by other malignancy-related mortality (29.9%) and CVD mortality (12.3%). The overall mortality risk was similar between the thyroid cancer and control groups (unadjusted hazard ratio (HR): 0.98; 95% confidence interval (CI): 0.88–1.10); the adjusted HR was 1.07 (95% CI: 0.95–1.20) after multivariate adjustment for age, gender, history of CVD, hyperlipidemia, diabetes mellitus, hypertension, and occupation. The risk of other malignancy-related mortality was comparable between two groups. CVD mortality risk was lower in the thyroid cancer group, with an unadjusted HR of 0.51 (95% CI: 0.38–0.69) and adjusted HR of 0.56 (95% CI: 0.42–0.76). In conclusion, patients with thyroid cancer had excellent overall survival. Thyroid cancer-specific mortality was the leading cause of death, highlighting the importance of thyroid cancer management. Thyroid cancer patients had lower CVD mortality risk than the general population.

Sign in / Sign up

Export Citation Format

Share Document